# Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

> **NCT02928419** · PHASE2 · TERMINATED · sponsor: **Associazione Qol-one** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Eltrombopag/Revolade
- **OTHER:** Placebo
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02928419
- **Lead sponsor:** Associazione Qol-one
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** "the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)"
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02928419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02928419, "Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02928419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*